We are incredibly proud to share that our Phase 1 study has been published in Nature, demonstrating a promising safety profile of our lead drug candidate 3-MMC. This marks a critical milestone in the development of an innovative treatment for PMS and PMDD.
What does this mean?
Our study demonstrates the safety of a novel treatment approach. With this publication, we take a crucial step towards delivering a solution that is backed by science.
A huge thank you to Maastricht University, Jan Raemakers, and the entire research team.
Why this matters:
- Women’s health remains one of the most underfunded areas in pharma, yet the demand for innovation is immense.
- PMS and PMDD affect 1 in 3 women, often leading to lost productivity and reduced quality of life
- Limited effective treatment options, lacking female specific MOA
- The pharmaceutical landscape is shifting—investors, biotech leaders, and researchers have a unique opportunity to support groundbreaking work in this space.
Read the full publication here: https://lnkd.in/ez-ZVJie
And this is just the beginning, our second paper is expected soon.
Follow us on LinkedIn to stay updated on the latest developments in this exciting journey!